Pacific Biosciences of California Inc. (NASDAQ:PACB) does about 4.71M shares in volume on a normal day but saw 3348084 shares change hands in Monday trading. The company now has a market cap of 2.56B USD. Its current market price is $11.33, marking an increase of 0.35% compared to the previous close of $11.29. The 52 week high reached by this stock is $14.20 whilst the lowest price level in 52 weeks is $3.85. The script in recent trading has seen the stock touch a high of $11.65 and a low of $10.94.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Pacific Biosciences of California Inc. (PACB) has a 20-day trading average at $9.59 and the current price is -20.21% off the 52-week high compared with 194.29% distance from its 52-week low. The 50-day simple moving average of the closing price is $9.77 and its 200-day simple moving average is $7.00. If we look at the stock’s price movements over the week, volatility stands at 8.12%, which increases to 8.27% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 63.76 to suggest the stock is neutral.
7 analysts observing the Pacific Biosciences of California Inc. (PACB) stock have set the 12-month price targets for the company’s shares at between $10.00 and $14.00. The consensus objective for the share price is $12.14, suggesting that the stock has a potential upside of 6.67% over the period. The median price target is 5.58% away from the current levels at $12.00.
FactSet Research has provided data showing that 7 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 4 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 20, 2023 when Cantor Fitzgerald downgraded the stock to “Neutral” and issued a price target of $12. Cantor Fitzgerald resumed its price target at $62-$31.
The current price level is 19.49%, 16.51%, and 62.15% away from its SMA20, SMA50, and SMA200 respectively, with the PACB price moving below the 50-day SMA on January 23. Pacific Biosciences of California Inc. (PACB) stock is up 3.38% over the week and 26.59% over the past month. Its price is 38.51% year-to-date and 9.05% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$0.34 below consensus estimates by -$0.01. The company’s next earnings report is expected on 05/03/2023, with forecasts estimating quarterly EPS at -$0.36 and -$1.38 for whole year. PACB’s earnings per share are forecast to shrink by -56.80% this year and 2.90% over next year. Expected sales for next quarter are $33.4 million, which analysts say will come at $127.91 million for the current fiscal year and next year at $175.43 million. In addition, estimates put the company’s current quarterly revenue at an average of $26.67 million.
Its 12-month price target is $12.00. To reach the target analysts have set, the stock logically needs to grow 6.67 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $10.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $14.00.
Outstanding shares total 225.12M with insiders holding 8.73% of the shares and institutional holders owning 90.06% of the company’s common stock. The company has a return on investment of -10.00% and return on equity of -42.20%. The beta has a value of 1.62. Price to book ratio is 4.08 and price to sales ratio is 18.70.
According to a U.S. Securities and Exchange Commission filing, ARK Innovation ETF has reduced its position in Pacific Biosciences of California Inc. (PACB) to 12,946,633 shares, mirroring a recent drop by -0.70%. ARK Innovation ETF dumped 91692.0 shares of Pacific Biosciences of California Inc. common stock bringing its total worth to about $105.9 million at the end of recent close, SEC documents show. ARK Innovation ETF isn’t the only investment manager who changed stakes and is followed by ARK Genomic Revolution ETF, which sold off 8167.0 shares to end up with 10,952,357 shares worth $89.59 million. American Funds Small Cap World Fu cut their holdings by -22.98% in the company over the course of the most recent quarter. It now holds a 3.48% position in Pacific Biosciences of California Inc. thanks to 7.88 million shares amounting to $64.43 million.
